Alnylam Pharmaceuticals, Inc. cash flow to debt ratio of 41.00% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Alnylam Pharmaceuticals, Inc.'s free cash flow has increased -1.19K% from $-42.59M last year to $465.38M, signaling increasing performance

Alnylam Pharmaceuticals, Inc.'s debt to equity ratio is 0.94, which means that the company's assets are unhealthy financed, signaling financial risk.

Alnylam Pharmaceuticals, Inc.'s debt has decreased relative to shareholder equity from 19.32 last year to 0.94 today, signaling strengthened financials

Alnylam Pharmaceuticals, Inc. has a net cash position, so leverage is healthy.

Alnylam Pharmaceuticals, Inc.'s interest coverage ratio of 3.08 indicates that earnings with margin can cover interest payments on company debt

Alnylam Pharmaceuticals, Inc.'s profit margin has increased (-235.94%) in the last year from -12.37% to 16.82%, signaling increasing performance

Alnylam Pharmaceuticals, Inc.'s short-term assets of $4.05B exceed its short-term liabilities of $1.47B

Alnylam Pharmaceuticals, Inc.'s return on assets of 14.54% is higher than the 5.00% threshold, indicating efficient asset utilization

Alnylam Pharmaceuticals, Inc.'s return on equity of 93.61%, is higher than 15.00%, indicating good performance

Alnylam Pharmaceuticals, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Alnylam Pharmaceuticals, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

Alnylam Pharmaceuticals, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Alnylam Pharmaceuticals, Inc. has a free cash flow yield of 1.60%, which is below the 2.00% threshold, indicating limited cash return relative to market value

Alnylam Pharmaceuticals, Inc.'s yearly earnings has increased -212.79% since last year from $-278.16M to $313.75M, signaling increasing performance

Alnylam Pharmaceuticals, Inc.'s yearly revenue has increased 65.19% since last year from $2.25B to $3.71B, signaling increasing performance

ROIC 24.43% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Alnylam Pharmaceuticals, Inc.'s 3-year revenue CAGR of 52.98% is positive, indicating growing revenue over the past 3 years

Alnylam Pharmaceuticals, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Alnylam Pharmaceuticals, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

Alnylam Pharmaceuticals, Inc. has insufficient data to evaluate this check.

Alnylam Pharmaceuticals, Inc. has an earnings yield of 2.79%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Alnylam Pharmaceuticals, Inc. is overvalued relative to its fair value price of 32.27 based on EBITDA multiple model

Alnylam Pharmaceuticals, Inc. has an EV/EBITDA ratio of 43.40x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Alnylam Pharmaceuticals, Inc. is overvalued relative to its fair value price of -82.37 based on Earnings Fair Value model

Alnylam Pharmaceuticals, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Alnylam Pharmaceuticals, Inc. has a price-to-book ratio of 21.35x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Alnylam Pharmaceuticals, Inc. has a price-to-sales ratio of 6.02x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue